Richard Sinnott
University of Melbourne, School of Engineering, Faculty Member
- Professor Richard O. Sinnott is the Director of eResearch at the University of Melbourne and Professor of Applied Com... moreProfessor Richard O. Sinnott is the Director of eResearch at the University of Melbourne and Professor of Applied Computing Systems. In these roles he is responsible for all aspects of eResearch (research-oriented IT development) at the University. He has been lead software engineer/architect on an extensive portfolio of national and international projects, with specific focus on those research domains requiring finer-grained access control (security).
IT security (authentication, authorisation, auditing and accounting systems)
biomedical IT systems (bioinformatics, life science data management)
clinical IT systems (biobanking, clinical trials, epidemiology, disease registries)
eResearch across multiple application areas (security, HPC, data management, distributed systems)
engineering IT systems (large scale supercomputing / Grids)
public health IT systems (social, clinical, geospatial, environmental systems)
social science IT systems (social simulation, microdata)
software engineering (real time systems, formal methods, distributed systems)edit
Niemann Pick Types A and B (NPA/B) diseases are autosomal recessive lysosomal storage disorders caused by the deficient activity of acid sphingomyelinase (ASM) due to mutations in the SMPD1 gene. Here, we provide a comprehensive updated... more
Niemann Pick Types A and B (NPA/B) diseases are autosomal recessive lysosomal storage disorders caused by the deficient activity of acid sphingomyelinase (ASM) due to mutations in the SMPD1 gene. Here, we provide a comprehensive updated review of already reported and newly identified SMPD1 variants. Among them, 185 have been found in NPA/B patients. Disease-causing variants are equally distributed along the SMPD1 gene; most of them are missense (65.4%) or frameshift (19%) mutations. The most frequently reported mutation worldwide is the p.R610del, clearly associated with an attenuated NP disease type B phenotype. The available information about the impact of 52 SMPD1 variants on ASM mRNA and /or enzymatic activity has been collected and whenever possible, phenotype/genotype correlations were established. In addition, we created a locus specific database easily accessible at http://www.inpdr.org/genes that catalogs the 417 SMPD1 variants reported to date and provides data on their in silico predicted effects on ASM protein function or mRNA splicing. The information reviewed in this paper, providing new insights into the genotype/phenotype correlation, is extremely valuable to facilitate diagnosis and genetic counseling of families affected by NPA/B. This article is protected by copyright. All rights reserved.
Research Interests:
BACKGROUND: The incidence of type 1 diabetes has increased worldwide, particularly in younger children and those with lower genetic susceptibility. These observations suggest factors in the modern environment promote pancreatic islet... more
BACKGROUND: The incidence of type 1 diabetes has increased worldwide, particularly in younger children and those with lower genetic susceptibility. These observations suggest factors in the modern environment promote pancreatic islet autoimmunity and destruction of insulin-producing beta cells. The Environmental Determinants of Islet Autoimmunity (ENDIA) Study is investigating candidate environmental exposures and gene-environment interactions that may contribute to the development of islet autoimmunity and type 1 diabetes. METHODS/DESIGN: ENDIA is the only prospective pregnancy/birth cohort study in the Southern Hemisphere investigating the determinants of type 1 diabetes in at-risk children. The study will recruit 1,400 unborn infants or infants less than six months of age with a first-degree relative (i.e. mother, father or sibling) with type 1 diabetes, across five Australian states. Pregnant mothers/infants will be followed prospectively from early pregnancy through childhood to investigate relationships between genotype, the development of islet autoimmunity (and subsequently type 1 diabetes), and prenatal and postnatal environmental factors. ENDIA will evaluate the microbiome, nutrition, bodyweight/composition, metabolome-lipidome, insulin resistance, innate and adaptive immune function and viral infections. A systems biology approach will be used to integrate these data. Investigation will be by 3-monthly assessments of the mother during pregnancy, then 3-monthly assessments of the child until 24 months of age and 6-monthly thereafter. The primary outcome measure is persistent islet autoimmunity, defined as the presence of autoantibodies to one or more islet autoantigens on consecutive tests. DISCUSSION: Defining gene-environment interactions that initiate and/or promote destruction of the insulin-producing beta cells in early life will inform approaches to primary prevention of type 1 diabetes. The strength of ENDIA is the prospective, comprehensive and frequent systems-wide profiling from early pregnancy through to early childhood, to capture dynamic environmental exposures that may shape the development of islet autoimmunity. TRIAL REGISTRATION: Australia New Zealand Clinical Trials Registry ACTRN12613000794707.
Research Interests:
Research Interests:
Research Interests:
As the global population continues to grow and an increasing number of people move to cities, there is need for ambitious approaches to provide urban information infrastructures and analytical tools to support smart urban design and... more
As the global population continues to grow and an increasing number of people move to cities, there is need for ambitious approaches to provide urban information infrastructures and analytical tools to support smart urban design and planning. This chapter introduces the Australian Urban Intelligence Network, which brings together a network of researchers, planners and policy-makers from across Australia who have access to an online workbench of data and tools. The workbench comprises over 1100 datasets and 100 spatial statistical routines, and a select number of planning support systems and geodesign tools. In this chapter, we outline the urban data and analytical capability the online workbench; introduce a couple of the PSS tools and spatial statistical capabilities through a case study approach. We also discuss the user outreach and capacity building capability program which is a critical component to assist with user adoption. We conclude the chapter with some reflections on the lessons learnt and next steps in the project.
Research Interests:
A wealth of information about adrenal cancer exists in many individual specialist centres around the world. The cancers themselves are very rare, often fatal and no common consensus on optimal treatment strategies exists, and certainly no... more
A wealth of information about adrenal cancer exists in many individual specialist centres around the world. The cancers themselves are very rare, often fatal and no common consensus on optimal treatment strategies exists, and certainly no treatments targeted to the individual genetic makeup of the tumours and individuals. In order to conduct effective and progressive research into these tumours and the surrounding conditions and treatments of individuals, it is essential to pool the expertise from specialist centres that exist in each country. The ENSAT-CANCER project is a 5-year European Union FP7-funded project tasked with this, through the development of an online environment that holds core data from a body of patients aligned with identified needs from leading specialists in the field. These data sets are also augmented with a host of tools and features that enable and support the research in this domain. This presentation will describe some of the novel features that have been developed in the project including biobank labelling and “match-making” services between centres. The presentation will also cover the hurdles involved in putting together such an enterprise – such as ethical approval for international data sharing and the establishment of canonical identification systems, and how these have been successfully overcome. The ENSAT-CANCER platform has now been used to support a portfolio of major international genetically targeted clinical trials and outcome studies. The presentation will describe the different processes involved in connecting and effectively sharing data and making best use of the ENSAT-CANCER platform.
Research Interests:
Angiogenesis is essential for tumor growth and metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor predominantly expressed in steroidogenic organs like the adrenal gland, ovary, testes,... more
Angiogenesis is essential for tumor growth and metastasis. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) is an angiogenic factor predominantly expressed in steroidogenic organs like the adrenal gland, ovary, testes, and placenta. EG-VEGF has antiapoptotic, mitogenic, and chemoattractive properties mediated via the two G protein-coupled receptors prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2). We investigated the expression of EG-VEGF and its receptors in a large number of normal adrenal glands (NAG), adrenocortical adenomas (ACA), and carcinomas (ACC) using real-time PCR (NAG, n = 12; ACA, n = 24; and ACC, n = 30) and immunohistochemistry (NAG, n = 9; ACA, n = 23; and ACC, n = 163) and evaluated its impact on patients’ survival. EG-VEGF, PKR1, and PKR2 mRNA and protein are expressed in NAG and the vast majority of ACA and ACC samples. The mean EG-VEGF mRNA expression was significantly lower in ACC (606.5 ± 77.1 copies) compared to NAG (4,043 ± 1,111) and cortisol-producing adenomas (CPA) (4,433 ± 2,378) (p < 0.01 and p < 0.05, respectively). However, cytoplasmic and nuclear EG-VEGF protein expression was either significantly higher or similar in ACC (H score 2.4 ± 0.05, p < 0.05 and 1.7 ± 0.08, n.s., respectively) compared to NAG (1.8 ± 0.14 and 1.7 ± 0.2). Nuclear protein expression of either EG-VEGF or PKR1 or both is predictive for a higher mortality compared to patients without nuclear expression (hazard ratio (HR) = 5.15; 95 % confidence interval (CI) = 1.24–21.36, n = 100, p = 0.02 independent of age, sex, and tumor stage). These findings suggest that EG-VEGF and its receptor PKR1 might play a role in the pathogenesis of adrenocortical tumors and could serve as prognostic markers for this rare malignant disease.
Research Interests:
Research Interests:
Grid technologies provide an infrastructure through which, amongst other things, data access and integration is facilitated across highly distributed and heterogeneous resources. Different domains have their own requirements on the nature... more
Grid technologies provide an infrastructure through which, amongst other things, data access and integration is facilitated across highly distributed and heterogeneous resources. Different domains have their own requirements on the nature of this data access and integration. The clinical domain offers arguably the greatest challenges facing the roll-out and adoption of Grid technologies to meet the changing face of post-genomic clinical research, especially with regard to information governance, ethics and hence security solutions. This paper outlines a novel system design for secure anonymous data access and linkage that meets the needs of key stakeholders in this space including end user researchers, data providers and owners and ethical oversight bodies amongst others. We identify how existing solutions developed within the Medical Research Council funded Virtual Organisations for Trials and Epidemiological Studies (VOTES) project are being re-factored to meet the needs of these ...
Research Interests:
The Avert-IT project (EU FP7) is an initiative to develop a system that can predict the onset of hypotensive events in patients over a feasible timescale (e.g. 15 mins) and allow clinicians to administer the appropriate treatment. To... more
The Avert-IT project (EU FP7) is an initiative to develop a system that can predict the onset of hypotensive events in patients over a feasible timescale (e.g. 15 mins) and allow clinicians to administer the appropriate treatment. To produce this system requires the additional development of a data collection platform, based at six leading clinical centres throughout Europe, with real-time
Research Interests:
ABSTRACT Breakthroughs in biomedicine are driven by research. More often than not, research takes place outside of a healthcare setting. However access to and use of clinical data for research purposes has many challenges that must be... more
ABSTRACT Breakthroughs in biomedicine are driven by research. More often than not, research takes place outside of a healthcare setting. However access to and use of clinical data for research purposes has many challenges that must be overcome, not least of which are the lack of standardized nomenclature and the heterogeneity of healthcare IT systems. For rare conditions, this challenge is particularly acute since the scarcity of data makes scientific breakthroughs increasingly difficult. Adrenal tumours represent one rare disease area where consolidation of clinical and biological information is urgently required. This paper describes the lessons being learnt in the development and rollout of an advanced security-oriented, virtual research environment (VRE) as part of the EU funded ENS@T-CANCER project. This system is currently used by 39 major cancer research centres across Europe and provides a unique resource for adrenal cancer research, underpinning an expanding portfolio of major international clinical trials and studies.
Research Interests:
Many e-Health strategies rely on the secure integration of datasets that have previously resided in isolated locations, but can now in principle be accessed over the Internet. Of paramount importance in the health domain is the need for... more
Many e-Health strategies rely on the secure integration of datasets that have previously resided in isolated locations, but can now in principle be accessed over the Internet. Of paramount importance in the health domain is the need for the security and privacy of data that is transmitted across these networks. One such collaboration, which spans several specialist centres across France, Germany, Italy and the UK, is ENSAT - the European Network for the Study of Adrenal Tumors. The rarity of the tumors under study means the value of accessing, aggregating and comparing data from many centres is great indeed. However this is especially challenging given that ENSAT require clinical and genomic data to be seamlessly linked, but in such a way that the information governance, ethics and privacy concerns of the patients and associated stakeholders involved are visibly satisfied. Key to this is the clear separation of clinical and genomic data sets and support for rigorous patient-identity...
Research Interests:
The very nature of rare diseases means that information is often sparse and highly distributed, and as a result progress in the field is more challenging to conduct. ENSAT-CANCER is an EU-FP7 funded initiative to develop a virtual... more
The very nature of rare diseases means that information is often sparse and highly distributed, and as a result progress in the field is more challenging to conduct. ENSAT-CANCER is an EU-FP7 funded initiative to develop a virtual research environment (VRE) offering a digitally interconnected infrastructure for distributed clinicians specialising in rare adrenal tumours to communicate and collaborate with distributed biomedical research communities. The core of the VRE is a registry that holds vital patient information from specialist centres around Europe, covering different types of adrenal tumours. The VRE also hosts a range of other enabling services including sample barcoding, bio-sample exchange mechanisms, an integrated linkage scheme to other trials and studies, summary statistics and report generation, image hosting - all of which are available in a seamless, security-driven environment. This paper presents the key challenges of this endeavour, the technical solutions that ...
Research Interests:
Research Interests:
Research Interests:
Abstract In this paper, a new index-based symmetric DNA encryption algorithm has been proposed. Adopting the methods of Block-Cipher and Index of string, the algorithm encrypts the DNA-sequence-based plaintext. First, the algorithm... more
Abstract In this paper, a new index-based symmetric DNA encryption algorithm has been proposed. Adopting the methods of Block-Cipher and Index of string, the algorithm encrypts the DNA-sequence-based plaintext. First, the algorithm encodes each character into ASCII ...
Research Interests:
ABSTRACT The use of Shibboleth as a mechanism for implementing federated authentication is commonplace in many countries. The ability of Shibboleth to transmit extra information about a user, including licenses, roles and other... more
ABSTRACT The use of Shibboleth as a mechanism for implementing federated authentication is commonplace in many countries. The ability of Shibboleth to transmit extra information about a user, including licenses, roles and other attributes, is not exploited for many reasons, mainly because institional Identity Providers (IdPs) are not maintainable sources of fine grained authorisation information. The JlSC-funded Shintau project has produced an extension to the Shibboleth profile which allows a user to link information from more than one IdP together utilising a custom Linking Service (LS). This paper describes both the application and independent evaluation of this software by the National e-Science Centre (NeSC) at the University of Glasgow within the context of the ESRC-funded Data Management through e-Social Science (DAMES) project.
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
A computational infrastructure to underpin complex clinical trials and medical population studies is highly desirable. This should allow access to a range of distributed clinical data sets; support the efficient processing and analysis of... more
A computational infrastructure to underpin complex clinical trials and medical population studies is highly desirable. This should allow access to a range of distributed clinical data sets; support the efficient processing and analysis of the data obtained; have security at its heart; and ensure that authorized individuals are able to see privileged data and no more. Each clinical trial has its own requirements on data sets and how they are used; hence a reusable and flexible framework offers many advantages. The MRC funded Virtual Organisations for Trials and Epidemiological Studies (VOTES) is a collaborative project involving several UK universities specifically to explore this space. This article presents the experiences of developing the Scottish component of this nationwide infrastructure, by the National e-Science Centre (NeSC) based at the University of Glasgow, and the issues inherent in accessing and using the clinical data sets in a flexible, dynamic and secure manner.
